Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$lexx Graphic](https://lunarcrush.com/gi/w:26/t:$lexx.png) $lexx

$LEXX surges on positive GLP-1 study results and potential licensing deals, with community excitement building. Human trial data is expected soon, fueling further anticipation.

### About $lexx
Lexaria Bioscience Corp. ($LEXX) is a company focused on drug delivery technology.  

### Insights [#](/topic/$lexx/insights)
- $lexx sentiment near a 52-week low at XX.
- $lexx engagements hit XXXXX which is XXX% higher than it's daily average.

### Engagements: XXXXX [#](/topic/$lexx/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$lexx/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$lexx/time-series/interactions.tsv)  
**Current Value**: XXXXX  
**Daily Average**: XXXXX  
**1 Week**: XXXXX -XXXX%  
**1 Month**: XXXXXX +87%  
**1-Year High**: XXXXXX on 2025-07-28  
**1-Year Low**: X on 2025-05-25  

| Social Network | X     |
| -------------- | -     |
| Engagements    | XXXXX |
  

  
  
### Mentions: XX [#](/topic/$lexx/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$lexx/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$lexx/time-series/posts_active.tsv)  
**Current Value**: XX  
**Daily Average**: XX  
**1-Year High**: XXX on 2025-06-27  
**1-Year Low**: X on 2025-05-05  

| Social Network | X   |
| -------------- | -   |
| Mentions       | XXX |
  

  
  
### Creators: X [#](/topic/$lexx/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$lexx/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$lexx/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $lexx in the last XX hours which is down XX% from X in the previous XX hours
**Daily Average**: XX  
**1 Month**: XX -XX%  
**1-Year High**: XXX on 2025-06-27  
**1-Year Low**: X on 2025-05-05  

The most influential creators that mention $lexx in the last XX hours

| Creator                                            | Rank | Followers | Posts | Engagements |
| -------                                            | ---- | --------- | ----- | ----------- |
| [@BarnyardBull72](/creator/twitter/BarnyardBull72) | X    | XXX       | X     | XXXXX       |
| [@wa7ermelon](/creator/twitter/wa7ermelon)         | X    | XXXXX     | X     | XXX         |

[View More](/list/creators/$lexx/100)
  
  
### Sentiment: XX% [#](/topic/$lexx/sentiment)
---
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$lexx/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$lexx/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% no change  
**1 Month**: XX% -XX%  
**1-Year High**: XXX% on 2025-04-27  
**1-Year Low**: XX% on 2025-08-04  

**Most Supportive Themes**
- **GLP-1 Studies and DehydraTECH:** (50%) Positive sentiment around Lexaria's DehydraTECH platform and its potential in GLP-1 studies, particularly in reducing side effects and its potential for partnerships with major pharmaceutical companies.
- **Potential Licensing Deals and Partnerships:** (30%) Speculation and anticipation regarding potential licensing deals and partnerships with major pharmaceutical companies, driving positive sentiment.
  
**Most Critical Themes**
- **Capital on Demand Sales Agreement Termination:** (10%)  The termination of a sales agreement, which could be interpreted negatively, although the impact appears limited based on the small number of shares sold.
  
Network engagement breakdown:  
| Network | Positive | %  | Neutral | %  | Negative | %  |
| ------- | -------- | -  | ------- | -  | -------- | -  |
| X       | XX       | X% | XXX     | X% | X        | X% |
|         |          |    |         |    |          |    |
| Total   | X        | X% | XXX     | X% | XX       | X% |
  


**Top assets mentioned**
In the posts about $lexx in the last XX hours

[Novo-Nordisk (NVO)](/topic/$nvo)
[Eli Lilly and Company (LLY)](/topic/eli-lilly)
[Eli Lilly and Company (LLY)](/topic/$lly)
[Pfizer, Inc. (PFE)](/topic/$pfe)
[BigBear.ai Holdings, Inc. (BBAI)](/topic/$bbai)
[BITMINE IMMERSION TECH (BMNR)](/topic/bitmine)
[BITMINE IMMERSION TECH (BMNR)](/topic/$bmnr)
[Merck & Co., Inc. (MRK)](/topic/$mrk)
[SharpLink Gaming (SBET)](/topic/sharplink)
[Amgen, Inc. (AMGN)](/topic/$amgn)

**Top topics mentioned**
In the posts about $lexx in the last XX hours

[stocks healthcare](/topic/stocks-healthcare), [$nvo](/topic/$nvo), [eli lilly](/topic/eli-lilly), [$lly](/topic/$lly), [$novcde](/topic/$novcde), [$pfe](/topic/$pfe), [acquisition](/topic/acquisition), [$jfb](/topic/$jfb), [$20m](/topic/$20m), [stocks bitcoin treasuries](/topic/stocks-bitcoin-treasuries), [$agmh](/topic/$agmh), [stocks crypto treasuries](/topic/stocks-crypto-treasuries), [$qmco](/topic/$qmco), [$bbai](/topic/$bbai), [$ipdn](/topic/$ipdn), [bitmine](/topic/bitmine), [coins gambling](/topic/coins-gambling), [$stkh](/topic/$stkh), [$elbm](/topic/$elbm), [investment](/topic/investment), [$spnt](/topic/$spnt), [$inab](/topic/$inab), [$plts](/topic/$plts), [$bmnr](/topic/$bmnr), [market cap](/topic/market-cap), [$mrk](/topic/$mrk), [sharplink](/topic/sharplink), [$mrm](/topic/$mrm), [$aqms](/topic/$aqms), [$nukk](/topic/$nukk), [$glto](/topic/$glto), [$rhhby](/topic/$rhhby), [$amgn](/topic/$amgn), [$tern](/topic/$tern), [$sbet](/topic/$sbet)

### Top Social Posts [#](/topic/$lexx/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$LEXX The market has no idea whats coming ✅ Oral GLP-1 platform ✅ Zero nausea ✅ MTA signed w/ Global Pharma ✅ Business development firm now engaged ✅ Human data readout this quarter ✅ Tiny $20M market cap ✅ Real acquisition setup forming $LEXX quietly solves the biggest problem in obesity drug history: tolerability + oral delivery. 👀 $PFE $NVO $LLY $MRK Position before Wall St wakes up. ⚡ $LEXX $LEXXW #GLP1 #biotech #MNA #obesity #stocks"  
[X Link](https://x.com/BarnyardBull72/status/1981000673081938273) [@BarnyardBull72](/creator/x/BarnyardBull72) 2025-10-22T14:12Z XXX followers, XXX engagements


"$TERN failed today due to Grade X liver enzyme elevations + vomiting-driven discontinuations. What does that signal The GLP-1 frontier is no longer just about efficacy its now a safety + tolerability engineering problem. Enter $LEXX @LexariaBioCorp 🔹 Solves GI burden (up to XXX% nausea elimination in human data) 🔹 Faster PK lower dose potential 🔹 Reduces hepatic load via lymphatic uptake 🔹 Platform works with semaglutide tirzepatide etc. If youre not connecting these dots pharma is. This setup has M&A written all over it. $NVO $PFE $LLY $MRK @EliLillyandCo @novonordiskus @pfizer @Merck"  
[X Link](https://x.com/BarnyardBull72/status/1980768042809504209) [@BarnyardBull72](/creator/x/BarnyardBull72) 2025-10-21T22:47Z XXX followers, XXX engagements


"🚨 $NVO Novo Nordisk board shake-up = Strategic shift moment 🚨 $LEXX Novos chairman just resigned after tension with its largest shareholder the Novo Nordisk Foundation. Why does this matter Because when foundations & mega-stakeholders apply pressure they demand growth protection of key markets and future-proofing revenue. What protects Wegovy/Ozempic billions Next-gen oral GLP-1 + better tolerability + patent extensions. Who has that tech $LEXX. ✅ XXX% nausea reduction in animals ✅ Faster delivery + lower dose potential ✅ CNS transport Alzheimers crossover potential ✅ Human GLP-1 data this"  
[X Link](https://x.com/BarnyardBull72/status/1980666198871486501) [@BarnyardBull72](/creator/x/BarnyardBull72) 2025-10-21T16:03Z XXX followers, 2597 engagements


"@BarnyardBull72 $lexx $nvo Makes sense for both Eli Lilly and Novo Nordisk to license/buyout DehydraTech"  
[X Link](https://x.com/wa7ermelon/status/1980654876595282320) [@wa7ermelon](/creator/x/wa7ermelon) 2025-10-21T15:18Z 5816 followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$lexx Graphic $lexx

$LEXX surges on positive GLP-1 study results and potential licensing deals, with community excitement building. Human trial data is expected soon, fueling further anticipation.

About $lexx

Lexaria Bioscience Corp. ($LEXX) is a company focused on drug delivery technology.

Insights #

  • $lexx sentiment near a 52-week low at XX.
  • $lexx engagements hit XXXXX which is XXX% higher than it's daily average.

Engagements: XXXXX #


Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
1 Week: XXXXX -XXXX%
1 Month: XXXXXX +87%
1-Year High: XXXXXX on 2025-07-28
1-Year Low: X on 2025-05-25

Social Network X
Engagements XXXXX

Mentions: XX #


Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
1-Year High: XXX on 2025-06-27
1-Year Low: X on 2025-05-05

Social Network X
Mentions XXX

Creators: X #


Creators Line Chart
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $lexx in the last XX hours which is down XX% from X in the previous XX hours Daily Average: XX
1 Month: XX -XX%
1-Year High: XXX on 2025-06-27
1-Year Low: X on 2025-05-05

The most influential creators that mention $lexx in the last XX hours

Creator Rank Followers Posts Engagements
@BarnyardBull72 X XXX X XXXXX
@wa7ermelon X XXXXX X XXX

View More

Sentiment: XX% #


Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% no change
1 Month: XX% -XX%
1-Year High: XXX% on 2025-04-27
1-Year Low: XX% on 2025-08-04

Most Supportive Themes

  • GLP-1 Studies and DehydraTECH: (50%) Positive sentiment around Lexaria's DehydraTECH platform and its potential in GLP-1 studies, particularly in reducing side effects and its potential for partnerships with major pharmaceutical companies.
  • Potential Licensing Deals and Partnerships: (30%) Speculation and anticipation regarding potential licensing deals and partnerships with major pharmaceutical companies, driving positive sentiment.

Most Critical Themes

  • Capital on Demand Sales Agreement Termination: (10%) The termination of a sales agreement, which could be interpreted negatively, although the impact appears limited based on the small number of shares sold.

Network engagement breakdown:

Network Positive % Neutral % Negative %
X XX X% XXX X% X X%
Total X X% XXX X% XX X%

Top assets mentioned In the posts about $lexx in the last XX hours

Novo-Nordisk (NVO) Eli Lilly and Company (LLY) Eli Lilly and Company (LLY) Pfizer, Inc. (PFE) BigBear.ai Holdings, Inc. (BBAI) BITMINE IMMERSION TECH (BMNR) BITMINE IMMERSION TECH (BMNR) Merck & Co., Inc. (MRK) SharpLink Gaming (SBET) Amgen, Inc. (AMGN)

Top topics mentioned In the posts about $lexx in the last XX hours

stocks healthcare, $nvo, eli lilly, $lly, $novcde, $pfe, acquisition, $jfb, $20m, stocks bitcoin treasuries, $agmh, stocks crypto treasuries, $qmco, $bbai, $ipdn, bitmine, coins gambling, $stkh, $elbm, investment, $spnt, $inab, $plts, $bmnr, market cap, $mrk, sharplink, $mrm, $aqms, $nukk, $glto, $rhhby, $amgn, $tern, $sbet

Top Social Posts #


Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"$LEXX The market has no idea whats coming ✅ Oral GLP-1 platform ✅ Zero nausea ✅ MTA signed w/ Global Pharma ✅ Business development firm now engaged ✅ Human data readout this quarter ✅ Tiny $20M market cap ✅ Real acquisition setup forming $LEXX quietly solves the biggest problem in obesity drug history: tolerability + oral delivery. 👀 $PFE $NVO $LLY $MRK Position before Wall St wakes up. ⚡ $LEXX $LEXXW #GLP1 #biotech #MNA #obesity #stocks"
X Link @BarnyardBull72 2025-10-22T14:12Z XXX followers, XXX engagements

"$TERN failed today due to Grade X liver enzyme elevations + vomiting-driven discontinuations. What does that signal The GLP-1 frontier is no longer just about efficacy its now a safety + tolerability engineering problem. Enter $LEXX @LexariaBioCorp 🔹 Solves GI burden (up to XXX% nausea elimination in human data) 🔹 Faster PK lower dose potential 🔹 Reduces hepatic load via lymphatic uptake 🔹 Platform works with semaglutide tirzepatide etc. If youre not connecting these dots pharma is. This setup has M&A written all over it. $NVO $PFE $LLY $MRK @EliLillyandCo @novonordiskus @pfizer @Merck"
X Link @BarnyardBull72 2025-10-21T22:47Z XXX followers, XXX engagements

"🚨 $NVO Novo Nordisk board shake-up = Strategic shift moment 🚨 $LEXX Novos chairman just resigned after tension with its largest shareholder the Novo Nordisk Foundation. Why does this matter Because when foundations & mega-stakeholders apply pressure they demand growth protection of key markets and future-proofing revenue. What protects Wegovy/Ozempic billions Next-gen oral GLP-1 + better tolerability + patent extensions. Who has that tech $LEXX. ✅ XXX% nausea reduction in animals ✅ Faster delivery + lower dose potential ✅ CNS transport Alzheimers crossover potential ✅ Human GLP-1 data this"
X Link @BarnyardBull72 2025-10-21T16:03Z XXX followers, 2597 engagements

"@BarnyardBull72 $lexx $nvo Makes sense for both Eli Lilly and Novo Nordisk to license/buyout DehydraTech"
X Link @wa7ermelon 2025-10-21T15:18Z 5816 followers, XXX engagements

$lexx
/topic/$lexx